Ireland - English - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - toldimfos sodium trihydrate - solution for injection - 20 %w/v - toldimfos - bovine, equine - food - vitamins & minerals

Ireland - English - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - toldimfos sodium trihydrate - solution for injection - 20 percent weight/volume - toldimfos - cattle, horses - vitamins and minerals

Canada - English - Health Canada

pfizer canada inc animal health group - sodium p-dimethyl amino orthololuene phosph trihyd; vitamin d3 (cholecalciferol) - solution - 100mg; 4000unit - sodium p-dimethyl amino orthololuene phosph trihyd 100mg; vitamin d3 (cholecalciferol) 4000unit - cattle; goats; horses; sheep; swine (pigs)

Canada - English - Health Canada

p.v.u., division of vÉtoquinol n.-a. inc. - sodium p-dimethyl amino orthololuene phosph trihyd - liquid - 100mg - sodium p-dimethyl amino orthololuene phosph trihyd 100mg - cattle; dog or cat; goats; horses; sheep; swine (pigs)

Singapore - English - HSA (Health Sciences Authority)

link healthcare singapore pte ltd - foscarnet trisodium hexahydrate - injection - 24 mg/ml - foscarnet trisodium hexahydrate 24 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - foscarnet sodium -

United States - English - NLM (National Library of Medicine)

clinigen limited - foscarnet sodium (unii: 964ys0oog1) (foscarnet - unii:364p9rvw4x) - foscarnet sodium 24 mg in 1 ml - foscavir is indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids). combination therapy with foscavir and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. safety and efficacy of foscavir have not been established for treatment of other cmv infections (e.g., pneumonitis, gastroenteritis); congenital or neonatal cmv disease; or nonimmunocompromised individuals. foscavir is indicated for the treatment of acyclovir-resistant mucocutaneous hsv infections in immunocompromised patients. safety and efficacy of foscavir have not been established for treatment of other hsv infections (e.g., retinitis, encephalitis); congenital or neonatal hsv disease; or hsv in nonimmunocompromised individuals. foscavir is contraindicated in patients with clinically significant hypersensitivity to foscarnet sodium.

United States - English - NLM (National Library of Medicine)

astrazeneca lp - foscarnet sodium (unii: 964ys0oog1) (foscarnet - unii:364p9rvw4x) - injection - 24 mg in 1 ml - foscavir is indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids). combination therapy with foscavir and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. safety and efficacy of foscavir have not been established for treatment of other cmv infections (e.g., pneumonitis, gastroenteritis); congenital or neonatal cmv disease; or nonimmunocompromised individuals. foscavir is indicated for the treatment of acyclovir-resistant mucocutaneous hsv infections in immunocompromised patients. safety and efficacy of foscavir have not been established for treatment of other hsv infections (e.g., retinitis, encephalitis); congenital or neonatal hsv disease; or hsv in nonimmunocompromised individuals. foscavir is contraindicated in patients with clinically significant hypersensitivity to foscarnet sodium.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - foscarnet sodium, quantity: 24 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid - treatment of cytomegalovirus (cmv) retinitis in patients with the acquired immunodeficiency syndrome (aids). indications as at 11 november 1994: for treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids); and treatment of aciclovir resistant herpes simplex virus (hsv) infections (defined by clinical trial or in-vitro resistance) in immunocompromised patients with human immunodeficiency virus (hiv) infection. note: the indication for treatment of aciclovir resistant hsv infections in immunocompromised patients with hiv infections is based primarily on the results of one open label comparative study. this was of patients with hiv infections and herpetic lesions unresponsive to aciclovir administered intravenously for 10 days or more and in-vitro documented resistance to aciclovir. eight patients were randomised to foscarnet (40mg/kg iv given eight hourly) and 6 were randomised to vidarabine 15mg/kg iv daily. the results showed a significant difference in favour o

United States - English - NLM (National Library of Medicine)

clinigen limited - foscarnet sodium (unii: 964ys0oog1) (foscarnet - unii:364p9rvw4x) - foscavir is indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids). combination therapy with foscavir and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. safety and efficacy of foscavir have not been established for treatment of other cmv infections (e.g., pneumonitis, gastroenteritis); congenital or neonatal cmv disease; or nonimmunocompromised individuals. foscavir is indicated for the treatment of acyclovir-resistant mucocutaneous hsv infections in immunocompromised patients. safety and efficacy of foscavir have not been established for treatment of other hsv infections (e.g., retinitis, encephalitis); congenital or neonatal hsv disease; or hsv in nonimmunocompromised individuals. foscavir is contraindicated in patients with clinically significant hypersensitivity to foscarnet sodium.